<code id='1A6F2BEA35'></code><style id='1A6F2BEA35'></style>
    • <acronym id='1A6F2BEA35'></acronym>
      <center id='1A6F2BEA35'><center id='1A6F2BEA35'><tfoot id='1A6F2BEA35'></tfoot></center><abbr id='1A6F2BEA35'><dir id='1A6F2BEA35'><tfoot id='1A6F2BEA35'></tfoot><noframes id='1A6F2BEA35'>

    • <optgroup id='1A6F2BEA35'><strike id='1A6F2BEA35'><sup id='1A6F2BEA35'></sup></strike><code id='1A6F2BEA35'></code></optgroup>
        1. <b id='1A6F2BEA35'><label id='1A6F2BEA35'><select id='1A6F2BEA35'><dt id='1A6F2BEA35'><span id='1A6F2BEA35'></span></dt></select></label></b><u id='1A6F2BEA35'></u>
          <i id='1A6F2BEA35'><strike id='1A6F2BEA35'><tt id='1A6F2BEA35'><pre id='1A6F2BEA35'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:2
          Chemotherapy infusion
          The White House outlined its efforts to end shortages of three key generic chemotherapies. But experts want more more details. Gerry Broome/AP

          WASHINGTON — The White House says it’s working to end shortages of three key generic chemotherapies. But experts said the administration would have to provide more details to fully mitigate the health care system’s concerns.

          Carboplatin, cisplatin, and methotrexate are three of 15 cancer drugs in shortage in the United States. They have been staples of cancer treatment for decades, according to a White House blog post, but their supply in the United States has been nearly halved in the past year. The shortages have forced doctors to ration the drugs and alter treatment plans, leaving cancer patients to wonder whether their survival odds are hurt.

          advertisement

          In its blog post, the White House noted that it’s now allowing Chinese imports of cisplatin. The Food and Drug Administration is also working with generic drug companies to boost production of all three drugs, but it didn’t say which companies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Tocagen's brain cancer gene therapy trial continues. Investors worry
          Tocagen's brain cancer gene therapy trial continues. Investors worry

          MichelleMonje/StanfordUniversity/NIHTocagen(TOCA)saidTuesdaythataPhase3clinicaltrialinvolvinganovelg

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          I learned firsthand about improving diversity in clinical trials

          Asthebiopharmaceuticalindustryplacesincreasedemphasisonimprovingthediversityofparticipantsinclinical